Oral Medication Shows Promise for Early Treatment of Diabetic Retinopathy
Researchers have demonstrated that an oral medication called Danegaptide can effectively target and repair damage to the retina's protective barrier in preclinical models, potentially offering a non-invasive alternative to current injectable treatments for diabetic eye disease. The drug rapidly reduced blood vessel leakage and retinal swelling while preventing breakdown of the inner blood-retina barrier. This advance could enable earlier treatment before irreversible vision loss occurs, addressing a condition affecting nearly 30% of people with diabetes.
Danegaptide addresses a fundamental clinical challenge in diabetes care: the timing of intervention. Currently, doctors can only treat retinopathy after vision loss has already begun, requiring patients to undergo repeated injections into the eye. The new oral approach targets the blood-retina barrier itself, the tissue structure that normally controls which substances enter the retina from circulating blood. When diabetes damages this barrier, fluid leaks into retinal tissue, causing swelling and progressive vision deterioration.
The preclinical research demonstrated rapid effects on leakage and swelling, while early human testing in 24 patients showed the drug was safe and produced early biological markers of improvement in over half of participants. However, these Phase Ib results represent preliminary data; researchers emphasize that larger, longer-term trials are needed to determine whether initial improvements translate into sustained vision protection over months and years of treatment.
If confirmed effective, this medication could reshape diabetic retinopathy management for tens of millions of people worldwide. An oral pill taken at home may enable treatment before irreversible damage occurs, potentially preventing blindness in working-age adults—a leading cause of vision loss in this population. The shift from invasive injections to preventive oral therapy could also improve patient adherence and access in regions with limited eye care infrastructure. However, the clinical impact depends on Phase II trials demonstrating long-term efficacy and identifying which patient populations benefit most.